Aquamephyton

Jaundice, Obstructive, long-acting anticoagulant rodenticides, Vitamin K Deficiency + 17 more

Treatment

10 FDA approvals

20 Active Studies for Aquamephyton

What is Aquamephyton

Phylloquinone

The Generic name of this drug

Treatment Summary

Vitamin K1 is a fat-soluble vitamin that helps the body form blood clots. It is used to treat conditions caused by a lack of vitamin K, such as coagulation disorders. Vitamin K1 has been manufactured since 1939 and was approved by the FDA before 1955.

Mephyton

is the brand name

image of different drug pills on a surface

Aquamephyton Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Mephyton

Phylloquinone

1955

65

Approved as Treatment by the FDA

Phylloquinone, also known as Mephyton, is approved by the FDA for 10 uses including Jaundice, Obstructive and Hypoprothrombinemia .

Jaundice, Obstructive

Used to treat Jaundice, Obstructive in combination with Taurocholic acid

Hypoprothrombinemia

Fistula, Biliary

Used to treat Fistula, Biliary in combination with Taurocholic acid

antibacterial therapy

Biliary Fistula

Used to treat Fistula, Biliary in combination with Taurocholic acid

hemorrhagic disease of the newborn

Hypoprothrombinemias

Jaundice, Obstructive

Used to treat Jaundice, Obstructive in combination with Taurocholic acid

Hemorrhagic Disease of Newborn

Salicylate

Effectiveness

How Aquamephyton Affects Patients

Phylloquinone is a vitamin K used to treat problems with blood clotting caused by a lack of vitamin K. It is effective for a long time and is safe to take in large doses. When taking this medication, it's important to monitor your prothrombin time and be aware of the possibility of allergic reactions if taken by injection.

How Aquamephyton works in the body

Vitamin K plays an important role in the body's clotting process. It helps convert certain proteins into their active form, so they can help form clots and stop bleeding. Vitamin K is also being studied for its role in keeping joints healthy and helping with bone density. It may also help prevent calcium buildup in the body's blood vessels.

When to interrupt dosage

The measure of Aquamephyton is contingent upon the diagnosed disorder, such as Sprue, Vitamin supplementation and Ulcerative Colitis. The quantity of dosage fluctuates as indicated by the mode of delivery outlined in the table below.

Condition

Dosage

Administration

long-acting anticoagulant rodenticides

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Vitamin supplementation therapy

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Vitamin supplementation

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Ulcerative Colitis

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

hemorrhagic disease of the newborn

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Anticoagulant Therapy

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Biliary Fistula

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

vitamin K

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Crohn Disease

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Blood Coagulation Disorders

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Celiac Disease

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Jaundice, Obstructive

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Vitamin K Deficiency

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Hypoprothrombinemias

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Intestinal resection

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Hemorrhagic Disease of Newborn

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Salicylate

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Cystic Fibrosis

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Celiac Disease

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

antibacterial therapy

, 5.0 mg, 10.0 mg/mL, 2.0 mg/mL, 1.0 mg, 0.2 mg/mL, 0.015 mg/mL, 0.15 mg/mL, 0.2 mg, 0.02 mg, 0.08 mg, 0.15 mg, 0.02 mg/mL, 0.1 mg/mL

, Tablet, Oral, Tablet - Oral, Injection, emulsion - Parenteral, Injection, emulsion, Parenteral, Emulsion, Liquid - Intramuscular, Liquid, Injection, solution - Intravenous, Capsule, Capsule - Oral, Intramuscular, Intramuscular; Intravenous; Subcutaneous, Injection, emulsion - Intramuscular; Intravenous; Subcutaneous, Intravenous, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Injection, solution, Liquid - Intravenous, Kit - Oral, Kit, Solution, Injection - Intravenous, Injection, Solution / drops, Solution / drops - Oral, Emulsion - Intramuscular; Intravenous; Subcutaneous, Intramuscular; Parenteral; Subcutaneous, Injection, solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Parenteral, Injection, emulsion - Intramuscular; Parenteral; Subcutaneous

Warnings

Aquamephyton has one contraindication, thus it should not be administered when suffering from the conditions set out in the following table.

Aquamephyton Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Phylloquinone may interact with Pulse Frequency

There are 20 known major drug interactions with Aquamephyton.

Common Aquamephyton Drug Interactions

Drug Name

Risk Level

Description

(R)-warfarin

Major

The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Phylloquinone.

(S)-Warfarin

Major

The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Phylloquinone.

4-hydroxycoumarin

Major

The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Phylloquinone.

Acenocoumarol

Major

The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Phylloquinone.

Clorindione

Major

The therapeutic efficacy of Clorindione can be decreased when used in combination with Phylloquinone.

Aquamephyton Toxicity & Overdose Risk

Taking high doses of vitamin K1 is not known to be toxic. However, when the vitamin is given intravenously, the risk of toxicity increases. Symptoms of toxicity should be treated with supportive care. The toxic dose of vitamin K1 for mice is 1170mg/kg when administered intravenously and greater than 24180mg/kg when taken orally.

Aquamephyton Novel Uses: Which Conditions Have a Clinical Trial Featuring Aquamephyton?

Currently, 100 active studies are being conducted to explore the potential of Aquamephyton to alleviate Crohn Disease, Hemorrhagic Disease of the Newborn and Obstructive Jaundice.

Condition

Clinical Trials

Trial Phases

Ulcerative Colitis

17 Actively Recruiting

Phase 3, Phase 2, Phase 1, Not Applicable, Phase 4

Jaundice, Obstructive

0 Actively Recruiting

Blood Coagulation Disorders

0 Actively Recruiting

Cystic Fibrosis

0 Actively Recruiting

Vitamin K Deficiency

0 Actively Recruiting

Vitamin supplementation

0 Actively Recruiting

Crohn Disease

0 Actively Recruiting

antibacterial therapy

0 Actively Recruiting

Hemorrhagic Disease of Newborn

0 Actively Recruiting

Celiac Disease

0 Actively Recruiting

Hypoprothrombinemias

0 Actively Recruiting

vitamin K

0 Actively Recruiting

hemorrhagic disease of the newborn

0 Actively Recruiting

Vitamin supplementation therapy

0 Actively Recruiting

long-acting anticoagulant rodenticides

0 Actively Recruiting

Celiac Disease

0 Actively Recruiting

Salicylate

0 Actively Recruiting

Anticoagulant Therapy

2 Actively Recruiting

Phase 4, Not Applicable

Intestinal resection

0 Actively Recruiting

Biliary Fistula

0 Actively Recruiting

Patient Q&A Section about aquamephyton

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is AquaMEPHYTON vitamin K used for?

"This medication is designed to help with vitamin K deficiency and bleeding in newborn babies."

Answered by AI

What is IV vitamin K called?

"Phytonadione is a vitamin that is used to prevent bleeding in people with blood clotting problems or who have too little vitamin K in their bodies."

Answered by AI

How is AquaMEPHYTON given to newborns?

"The American Academy of Pediatrics recommends that newborns receive a single intramuscular dose of vitamin K1 within one hour of birth. However, this should not replace a proper laboratory evaluation of the coagulation mechanism."

Answered by AI

Is AquaMEPHYTON the same as vitamin K?

"AquaMEPHYTON is a yellow, sterile, aqueous colloidal solution of vitamin K1, available for injection by the intravenous, intramuscular, and subcutaneous routes. AquaMEPHYTON is available in 1 mg (2 mg/mL) and 10 mg (10 mg/mL) single-dose ampuls."

Answered by AI

Clinical Trials for Aquamephyton

Image of Resilient Roots: Functional Medicine in Charlottesville, United States.

Ketogenic and Carnivore Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

18 - 64
All Sexes
Charlottesville, VA

This study is a randomized controlled clinical trial evaluating whether two therapeutic dietary approaches - a ketogenic diet and a carnivore (lion) diet - can improve quality of life, reduce symptoms, and influence measures of disease activity in adults with inflammatory bowel disease \[ulcerative colitis and Crohn's disease\] (IBD) or rheumatoid arthritis (RA). Participants will be randomized into one of three groups: 1) Ketogenic Diet, 2) Carnivore (Lion) Diet or 3) Wait-List Control. Participants randomized to a dietary group (ketogenic diet or carnivore diet) will be provided guidance on their specific dietary therapy and answer questions about their symptoms and quality of life at different intervals over a 24 week period. Participants will also complete laboratory testing at different intervals to assess for changes in nutritional status, cardiometabolic health and markers of immune activation and inflammation. Participants initially placed on the wait-list group will be asked similar questions about their symptoms and quality of life and complete the same laboratory testing as participants in a dietary group. Participants on the wait list will then be compared to participants following a specific dietary pattern to assess for any differences between the 2 groups. After 12 weeks, participants on the wait list will be randomized to a dietary group (ketogenic diet or carnivore diet) and followed in a similar fashion for an additional 12 week period.

Recruiting
Has No Placebo

Resilient Roots: Functional Medicine

Robert D Abbott, MD

Image of UCSF Medical Center in San Francisco, United States.

Upadacitinib for Ulcerative Colitis

18 - 75
All Sexes
San Francisco, CA

The goal of this clinical trial is to learn if the oral medication upadacitinib can safely and effectively treat acute severe ulcerative colitis (ASUC) in adults who are hospitalized. It will also evaluate whether upadacitinib can be used without corticosteroids during initial treatment. The main questions it aims to answer are: 1. Does upadacitinib reduce treatment failure by Day 14 (defined as need for colectomy or rescue therapy)? 2. What side effects and safety events occur when using upadacitinib in hospitalized patients with ASUC? Researchers will compare outcomes in participants receiving upadacitinib to a historical group of similar patients previously treated with standard therapies, including intravenous corticosteroids and infliximab, to determine if upadacitinib improves outcomes. Participants will: 1. Take oral upadacitinib once daily during hospitalization. 2. Undergo routine clinical monitoring, including blood tests and symptom assessments. 3. Be followed after discharge with clinic visits or phone calls for up to 12 months to assess outcomes such as need for additional treatment, surgery, and safety events

Phase 4
Waitlist Available

UCSF Medical Center

Sara Lewin, MD

AbbVie

Have you considered Aquamephyton clinical trials?

We made a collection of clinical trials featuring Aquamephyton, we think they might fit your search criteria.
Go to Trials
Image of McMaster Children's Hospital - Digestive Diseases Clinic in Hamilton, Canada.

Vancomycin for Ulcerative Colitis

18+
All Sexes
Hamilton, Canada

This clinical trial tests if oral vancomycin can safely treat active ulcerative colitis (UC) in adults who also have primary sclerosing cholangitis (PSC), a liver condition. The main questions it aims to answer are: * Can oral vancomycin improve UC symptoms as measured by Mayo score at 4 weeks? * Is oral vancomycin safe and tolerable in this patient group? Participants will be compared to see if vancomycin works better than placebo. Participants will: * Take oral vancomycin (250 mg twice daily) or identical placebo capsules for 4 weeks * Have the option for 4 more weeks of open-label vancomycin after the blinded phase * Attend clinic visits at baseline, week 4, and follow-up for Mayo scoring, endoscopy, blood/stool tests, and safety checks * Track treatment adherence and side effects The study primarily assesses if the trial can recruit 14 participants, retain them, achieve good adherence, and follow protocol procedures (feasibility). Secondary goals include safety (adverse events) and early signs of benefit in UC activity, liver tests, and gut bacteria balance. This pilot will guide larger future studies.

Phase 2
Waitlist Available

McMaster Children's Hospital - Digestive Diseases Clinic

Neeraj Narula, MD

Image of MUHC - Montreal General Hospital in Montreal, Canada.

Ustekinumab for Crohn's Disease and Ulcerative Colitis

18+
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST). The main question it aims to answer is: Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission. Participants will: Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Phase 4
Recruiting

MUHC - Montreal General Hospital

Janssen Inc.

Have you considered Aquamephyton clinical trials?

We made a collection of clinical trials featuring Aquamephyton, we think they might fit your search criteria.
Go to Trials
Image of Victoria Hospital - London Health Sciences Centre in London, Canada.

Vitamin D for Inflammatory Bowel Disease

18 - 85
All Sexes
London, Canada

The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are: 1. What proportion of IBD patients adhere to Vitamin D supplement recommendations over a 12-month period? 2. Is the ASK-12 Questionnaire valid in measuring adherence among IBD patients? 3. Does the severity of a patient's Crohn's disease effect overall adherence, over a 12-month period? 4. Does the severity of a patient's Ulcerative Colitis disease effect overall adherence, over a 12-month period? 5. Does Vitamin D supplementation affect the health-related Quality of Life for IBD patients? 6. Is 2,000 IU/Day an effective dose to sustain appropriate blood Vitamin D levels among previously Vitamin deficient IBD patients? Participants will: * Take 2000 IU of Vitamin D every day for the next 12 months * Complete 2 surveys, bloodwork and a fecal calprotectin test at the initial, visit, 6 month follow up and 12 month follow up

Phase 1
Waitlist Available

Victoria Hospital - London Health Sciences Centre

Terry Ponich, MD

Image of Toronto Immune and Digestive Health Institute in North York, Canada.

Healing Circuits™ for Inflammatory Bowel Disease

18 - 75
All Sexes
North York, Canada

The purpose of this study is to test the impact of Healing Circuits™; a structured mental health support model on IBD patients. The eligible study participants will be randomly divided into two groups: 1. the group receiving structured mental health support with a social worker and 2. the group receiving structured mental health support via a self-directed online curriculum. Both groups will be receiving the same type of therapy, Healing Circuits™, but the group receiving the therapy via the online self-directed curriculum will be receiving the therapy mostly by web-based video instruction. The two groups will be evaluated over a period of 12 months.

Recruiting
Has No Placebo

Toronto Immune and Digestive Health Institute

Mark Silverberg, MD, PhD

Amgen

Image of Carolina Digestive Diseases- Site Number : 8400013 in Greenville, United States.

SAR441566 for Ulcerative Colitis

18 - 75
All Sexes
Greenville, NC

This is a Phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate-to-severe UC. The primary objective of this study is to assess efficacy of different doses of SAR441566 on clinical remission in participants with moderate-to-severe ulcerative colitis. This study will include a screening period of up to 28 days (+ 7 calendar days if needed) followed by the main study treatment period of 52 weeks which will be comprised of a double blind (DB) treatment period with 12 weeks of induction period followed by a maintenance period of 40 weeks and 2-week follow-up after end of treatment. Additionally, an Open Label (OL) period of up to 40 weeks will be offered to eligible participants (for participants not enrolling in the LTS study). * The study duration will be up to 59 weeks. * The treatment duration will be up to 52 weeks in the DB arm and up to 40 weeks in the OL arm. * The number of visits will be 12 for the main study treatment period and 8 for the OL treatment period.

Phase 2
Recruiting

Carolina Digestive Diseases- Site Number : 8400013 (+28 Sites)

Sanofi

Have you considered Aquamephyton clinical trials?

We made a collection of clinical trials featuring Aquamephyton, we think they might fit your search criteria.
Go to Trials